{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:39:28Z","timestamp":1790239168967,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.chest.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T02:32:15Z","timestamp":1497666735000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pulmonary Hypertension in Parenchymal Lung Diseases"],"prefix":"10.1016","volume":"153","author":[{"given":"Sergio","family":"Harari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2017.06.008_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1183\/13993003.01684-2015","article-title":"Resting pulmonary artery pressure of 21-24\u00a0mm\u00a0Hg predicts abnormal exercise haemodynamics","volume":"47","author":"Lau","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2017.06.008_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MCP.0000000000000084","article-title":"Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis","volume":"20","author":"Adir","year":"2014","journal-title":"Curr Opin Pulm Med"},{"issue":"129","key":"10.1016\/j.chest.2017.06.008_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1183\/09059180.00002713","article-title":"Pulmonary hypertension in chronic interstitial lung disease","volume":"22","author":"Caminati","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.chest.2017.06.008_bib5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib6","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"Nadrous","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2017.06.008_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00408-011-9293-4","article-title":"Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease","volume":"189","author":"Stone","year":"2011","journal-title":"Lung"},{"issue":"5","key":"10.1016\/j.chest.2017.06.008_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1378\/chest.12-1330","article-title":"Out of proportion pulmonary hypertension: a paradigm for rare diseases","volume":"142","author":"Harari","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2017.06.008_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1164\/rccm.201105-0813ED","article-title":"End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis","volume":"184","author":"Noble","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2017.06.008_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2017.06.008_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2017.06.008_bib13","unstructured":"Bayer Press Release. Bayer terminates phase II study with riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. http:\/\/www.prnewswire.com\/news-releases\/bayer-terminates-phase-ii-study-with-riociguat-in-patients-with-pulmonary-hypertension-associated-with-idiopathic-interstitial-pneumonias-300267616.html. Accessed June 16,\u00a02017."},{"issue":"5","key":"10.1016\/j.chest.2017.06.008_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/resp.12294","article-title":"Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors","volume":"19","author":"Zimmermann","year":"2014","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.chest.2017.06.008_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A\u00a0controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2017.06.008_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.chest.2017.06.008_bib17","doi-asserted-by":"crossref","first-page":"e0141911","DOI":"10.1371\/journal.pone.0141911","article-title":"Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias","volume":"10","author":"Hoeper","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.chest.2017.06.008_bib18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/thoraxjnl-2014-205337","article-title":"The good the bad and the ugly","volume":"69","author":"Corris","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.chest.2017.06.008_bib19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.chest.2017.06.008_bib20","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2017.06.008_bib21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1183\/13993003.01110-2015","article-title":"Pulmonary hypertension associated with ponatinib therapy","volume":"47","author":"Quillot","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2017.06.008_bib22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1183\/13993003.01410-2016","article-title":"Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity","volume":"48","author":"Riou","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2017.06.008_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/CIRCULATIONAHA.113.004555","article-title":"Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay","volume":"129","author":"Huertas","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2017.06.008_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000431380","article-title":"Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.","volume":"90","author":"Girard","year":"2015","journal-title":"Respiration"},{"key":"10.1016\/j.chest.2017.06.008_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A\u00a0randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2017.06.008_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(96)90011-2","article-title":"Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease","volume":"347","author":"Barber\u00e0","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2017.06.008_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1753465808103499","article-title":"Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease","volume":"3","author":"Valerio","year":"2009","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.00176312","article-title":"Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial","volume":"42","author":"Blanco","year":"2013","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S2213-2600(14)70013-X","article-title":"Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial","volume":"2","author":"Goudie","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2017.06.008_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib31","first-page":"460","article-title":"Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation","volume":"16","author":"Harari","year":"1997","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib32","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1378\/chest.111.4.1142-a","article-title":"Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension","volume":"111","author":"Harari","year":"1997","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2017.06.008_bib33","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1378\/chest.11-2490","article-title":"Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies","volume":"142","author":"Le Pavec","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2017.06.008_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1183\/09031936.00093111","article-title":"Pulmonary hypertension in\u00a0lymphangioleiomyomatosis: characteristics in 20 patients","volume":"40","author":"Cottin","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2017.06.008_bib35","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","author":"Baughman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2017.06.008_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2012.01.083","article-title":"Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials","volume":"60","author":"Savarese","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2017.06.008_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","article-title":"Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials","volume":"126","author":"Gabler","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2017.06.008_bib38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1513\/pats.200803-029SK","article-title":"Surrogate and combined end points in pulmonary arterial hypertension","volume":"5","author":"Ventetuolo","year":"2008","journal-title":"Proc Am Thorac Soc"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217310772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217310772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:01:17Z","timestamp":1757923277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369217310772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0012369217310772"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2017.06.008","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Hypertension in Parenchymal Lung Diseases","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}